CDKI-73 is primarily used in research settings as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK9. Its application is significant in the study of cancer biology, as CDK9 plays a crucial role in transcriptional regulation and cell cycle progression. By inhibiting CDK9, it helps researchers understand the mechanisms of cancer cell proliferation and survival. Additionally, CDKI-73 is utilized in preclinical studies to evaluate its potential as a therapeutic agent for various cancers, including leukemia and solid tumors. Its ability to induce apoptosis and suppress tumor growth makes it a valuable tool in the development of targeted cancer therapies.